Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 6, 2005, Pages 577-583

  Hayward, R L ^a   Schornagel, Q C ^a   Tente, R ^a   Macpherson, J S ^a   Aird, R E ^a   Guichard, S ^a   Habtemariam, A ^a   Sadler, P ^a   Jodrell, D I ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Apoptosis; Colorectal cancer; RM175; Ruthenium

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOTOXIC AGENT; LIPOCORTIN 5; ORGANOMETALLIC COMPOUND; PROTEIN BAX; PROTEIN P53; RHODAMINE; RM 175; RUTHENIUM COMPLEX; SULFUR DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EXPOSURE; DRUG RESPONSE; HUMAN; HUMAN CELL; IC 50; NULL CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL CYCLE; CELL CYCLE PROTEINS; CELL SURVIVAL; CLONING, MOLECULAR; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HUMANS; IMMUNOBLOTTING; INHIBITORY CONCENTRATION 50; ORGANOMETALLIC COMPOUNDS; PROTO-ONCOGENE PROTEINS C-BCL-2; RUTHENIUM; TUMOR SUPPRESSOR PROTEIN P53;

EID: 18744371055     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0932-9     Document Type: Article

References (32)

1. Chen H, Parkinson JA, Parsons S, Coxall RA, Gould RO, Sadler PJ (2002) Organometallic ruthenium(II) diamine anti-cancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts. J Am Chem Soc 124:3064-3082
2. Morris RE, Aird RE, Murdoch Pdel S, Chen H, Cummings J, Hughes ND, Parsons S, Parkin A, Boyd G, Jodrell DI, Sadler PJ (2001) Inhibition of cancer cell growth by ruthenium(II) arene complexes. J Med Chem 44:3616-3621
3. Novakova O, Chen H, Vrana O, Rodger A, Sadler PJ, Brabec V (2003) DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media. Biochemistry 42:11544-11554
4. Chen H, Parkinson JA, Morris RE, Sadler PJ (2003) Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms. J Am Chem Soc 125:173-186
5. Aird RE, Cummings J, Ritchie AA, Muir M, Morris RE, Chen H, Sadler PJ, Jodrell DI (2002) In vitro and In vivo activity and cross resistance profiles of novel ruthenium(II) organometallic arene complexes in human ovarian cancer. Br J Cancer 86:1652-1657
6. Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C, Levrero M (2002) DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell 9:175-186
7. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr, Levrero M, Wang JY (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399:806-809
8. Nehme A, Baskaran R, Nebel S, Fink D, Howell SB, Wang JY, Christen RD (1999) Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer 79:1104-1110
9. Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD, Howell SB (2001) P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res 61:1508-1516
10. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263-269
11. el-Deiry WS (1998) Regulation of p53 downstream genes. Semin Cancer Biol 8:345-357
12. Gupta M, Fan S, Zhan Q, Kohn KW, O'Connor PM, Pommier Y (1997) Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin Cancer Res 3:1653-1660
13. te Poele RH, Joel SP (1999) Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines. Br J Cancer 81:1285-1293
14. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B (1999) 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401:616-620
15. Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B (2000) Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev 14:1584-1588
16. Bartke T, Siegmund D, Peters N, Reichwein M, Henkler F, Scheurich P, Wajant H (2001) p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 20:571-580
17. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW (2004) Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23:2934-2949
18. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B (2001) PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7:673-682
19. Lutz RJ (2000) Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins. Biochem Soc Trans 28:51-56
20. Zha J, Harada H, Osipov K, Jockel J, Waksman G, Korsmeyer SJ (1997) BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J Biol Chem 272:24101-24104
21. Yin XM, Oltvai ZN, Korsmeyer SJ (1994) BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369:321-323
22. Reed JC (1996) Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Behring Inst Mitt 97:72-100
23. Chao DT, Korsmeyer SJ (1998) BCL-2 family: regulators of cell death. Annu Rev Immunol 16:395-419
24. Korsmeyer SJ (1999) BCL-2 gene family and the regulation of programmed cell death. Cancer Res 59:1693s-1700s
25. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B (2000) Role of BAX in the apoptotic response to anticancer agents. Science 290:989-992
26. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501
27. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI (2003) Antisense Bcl-x1 down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clin Cancer Res 9:2856-2865
28. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI (2004) Enhanced oxaliplatin-induced apoptosis following antisense Bcl-x1 down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol Cancer Ther 3:169-178
29. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112
30. Clodi K, Kliche KO, Zhao S, Weidner D, Schenk T, Consoli U, Jiang S, Snell V, Andreeff M (2000) Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes. Cytometry 40:19-25
31. Schmitt CA, Rosenthal CT, Lowe SW (2000) Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 6:1029-1035
32. Schmitt CA, Lowe SW (2002) Apoptosis and chemoresistance in transgenic cancer models. J Mol Med 80:137-146